Computed tomography has been introduced as a noninvasive imaging modality used for coronary artery calcium scoring in asymptomatic individuals and contrast-enhanced coronary angiography in symptomatic individuals. As the rising costs of healthcare reflect, in part, the development of these types of new expensive technologies for cardiac diagnosis, the economic considerations that surround them should be of interest to clinicians and payers alike. In this review, we discuss basic principles underlying economic efficiency analyses of medical products, using computed tomography in coronary artery disease as a case in point.